| PATENT REGISTER | |||||||||||||||||||||||||||||||
| A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2014/004 | |||||||||||||||||||||||||||||||
| Status | Expired | Patent No. | 1381356 | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application No. | 02763962.4 | Date of Filing | 04/04/2002 | ||||||||||||||||||||||||||||
| Date Grant Published | 28/05/2008 | Application Published | 21/01/2004 | ||||||||||||||||||||||||||||
| Title of Invention | USE OF (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID-(4'-TRIFLUOROMETHYLPHENYL)-AMIDE FOR TREATING MULTIPLE SCLEROSIS | ||||||||||||||||||||||||||||||
| Priority |
|
||||||||||||||||||||||||||||||
| Inventor | WETTSTEIN, Joseph | ||||||||||||||||||||||||||||||
| Current Proprietor |
Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 65926 Frankfurt am Main GERMANY |
||||||||||||||||||||||||||||||
| Address for service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||||||||||||||||||||||||||||||
| Renewal Fees |
|
||||||||||||||||||||||||||||||
| Publication Language | English | ||||||||||||||||||||||||||||||
| Translation Received Date | |||||||||||||||||||||||||||||||
| 17/07/2008 | Divisional Application number: 08004647.7 Date of receipt: 13/03/2008 | ||||||||||||||||||||||||||||||
| 25/07/2008 | Address for Service recorded as F.R. KELLY & CO. 27 Clyde Road, Ballsbridge, Ireland received on 23/07/08. | ||||||||||||||||||||||||||||||
| 29/01/2014 | Request for grant a Supplementary Protection Certificate, citing Patent number 1381356 as the relevant basic patent, in respect of the product Teriflunomide, its stereoisomer and pharmaceutically acceptable salts thereof filed on 24/01/2014. Reference number of request is 2014/004. | ||||||||||||||||||||||||||||||
| 08/06/2015 | Supplementary Protection Certificate Number 2014/004, having an expiry date of 03/04/2027 granted on 08/06/2015. | ||||||||||||||||||||||||||||||
| 21/07/2016 | Change of Proprietorship from Aventis Pharmaceuticals Inc., 55 Corporate Drive, Bridgewater, NJ 08807, United States of America to Aventisub LLC, 3711 Kennett Pike, Suite 200, Greenville, Delaware 19807, United States of America, by virtue of Certificate of Merger, dated 18/06/2014. | ||||||||||||||||||||||||||||||
| 09/05/2019 | Change of Proprietorship from Aventisub LLC, 3711 Kennett Pike, Suite 200, Greenville, Delaware 19807, United States of America to Sanofi-Aventis Deutschland GmbH, Brüningstrasse 50, 65926 Frankfurt am Main, Germany, by virtue of Deed of Assignment, dated 29/01/2019. | ||||||||||||||||||||||||||||||
| 03/05/2022 | Patent expired on 03/04/2022. | ||||||||||||||||||||||||||||||
